Nuvectra seeking FDA conditional approval for full-body MR imaging for Algovita

Nuvectra (NASDAQ:NVTR) filed a regulatory submission with the FDA for conditional approval of full-body magnetic resonance (MR) imaging in patients implanted with the company’s Algovita spinal cord stimulation (SCS) system.

Algovita consists of 24-channel implantable pulse generators to manage pain.

“We believe full-body MR-conditional approval in the United States, in addition to Algovita’s full-body MR-conditional CE mark approval, will supplement our existing competitive advantages and expand the number of eligible patients,” Fred Parks, Nuvectra’s CEO, said in a statement.

Nuvectra expects the FDA’s decision around the end of 2019.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.